الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 179 |  |  |
| | | from | 179 | | |
Abstract
Background: Over the past 2 decades, Non Alcoholic Fatty Liver Disease has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world. In fact, 25% of the world’s population is currently thought to have NAFLD
Objective: To assess hepatic steatosis and fibrosis by Vibration Controlled Transient Elastography (VCTE) versus other non-invasive assessment scores in Egyptian patients with non-alcoholic fatty liver disease.
Patients and Methods: This study assessed the performance characteristics of (VCTE) versus other non-invasive methods for evaluation of steatosis and fibrosis in NAFLD patients. 90 cases with NAFLD were selected and evaluated.
Results: We found that, there is significant correlation between liver steatosis and fibrosis detected with Fibroscan Liver stiffness measurement (LSM) & Controlled attenuation parameter (CAP) and non-invasive scores for steatosis (Fatty Liver Index) and fibrosis (APRI & FIB-4 &NFS).
The best cut off of steatosis detecting by Fibroscan vsFLI score is 220,50 which fulfill the highest sensitivity and specificity (sensitivity 86.00%, specificity 65.0%) with accuracy equal to 85.65%. The best cut off of fibrosis detecting by Fibroscan vs. APRI, FIB-4, NFS scores is overall average 5.2, which fulfill the highest sensitivity and specificity (sensitivity 85.30%, specificity 47.70%) with accuracy equal to 85.48% (AUC 0.742).
Conclusion: Fibroscan can be used as a screening method for patients suspected with NAFLD or patient without clear indication for liver biopsy but liver biopsy remains the golden standard for the diagnosis, staging and evaluation for NAFLD.